BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35181378)

  • 1. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
    Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
    Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature.
    Koelsche C; Benhamida JK; Kommoss FKF; Stichel D; Jones DTW; Pfister SM; Heilig CE; Fröhling S; Stenzinger A; Buslei R; Mentzel T; Baumhoer D; Ladanyi M; Antonescu CR; Flucke U; Gorp JV; Bode-Lesniewska B; Deimling AV; Mechtersheimer G
    Mod Pathol; 2021 Dec; 34(12):2122-2129. PubMed ID: 34312479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DDIT3-amplified or low-polysomic pleomorphic sarcomas without MDM2 amplification: Clinicopathological review and immunohistochemical profile of nine cases.
    Mori T; Iwasaki T; Sonoda H; Kawaguchi K; Tomonaga T; Furukawa H; Sato C; Shiraishi S; Taguchi K; Tamiya S; Yoneda R; Oshiro Y; Matsunobu T; Abe C; Kuboyama Y; Ueki N; Kohashi K; Yamamoto H; Nakashima Y; Oda Y
    Hum Pathol; 2024 Mar; 145():56-62. PubMed ID: 38401716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 dual-color in situ hybridization (DISH) aids the diagnosis of intimal sarcomas.
    Jimbo N; Komatsu M; Itoh T; Hirose T
    Cardiovasc Pathol; 2019; 43():107142. PubMed ID: 31442826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
    Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
    Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intimal Sarcoma with MDM2/CDK4 Amplification and p16 Overexpression: A Review of Histological Features in Primary Tumor and Xenograft, with Immunophenotype and Molecular Profiling.
    Giner F; Machado I; Rubio-Martínez LA; López-Guerrero JA; Claramunt-Alonso R; Navarro S; Ferrández A; Mayordomo-Aranda E; Llombart-Bosch A
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
    Biernat W; Debiec-Rychter M; Liberski PP
    Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas.
    Neuville A; Collin F; Bruneval P; Parrens M; Thivolet F; Gomez-Brouchet A; Terrier P; de Montpreville VT; Le Gall F; Hostein I; Lagarde P; Chibon F; Coindre JM
    Am J Surg Pathol; 2014 Apr; 38(4):461-9. PubMed ID: 24625414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis.
    Ito M; Barys L; O'Reilly T; Young S; Gorbatcheva B; Monahan J; Zumstein-Mecker S; Choong PF; Dickinson I; Crowe P; Hemmings C; Desai J; Thomas DM; Lisztwan J
    Clin Cancer Res; 2011 Feb; 17(3):416-26. PubMed ID: 21159888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.
    Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA
    Int J Cancer; 2018 Jan; 142(1):57-65. PubMed ID: 28891048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
    Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
    Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
    Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
    J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
    Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
    Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 in bone and soft tissue sarcomas.
    Thoenen E; Curl A; Iwakuma T
    Pharmacol Ther; 2019 Oct; 202():149-164. PubMed ID: 31276706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation.
    Kanoe H; Nakayama T; Murakami H; Hosaka T; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Sasaki MS; Toguchida J
    Anticancer Res; 1998; 18(4A):2317-21. PubMed ID: 9703873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.
    Lin DI; Hemmerich A; Edgerly C; Duncan D; Severson EA; Huang RSP; Ramkissoon SH; Connor YD; Shea M; Hecht JL; Ali SM; Vergilio JA; Ross JS; Elvin JA
    Gynecol Oncol; 2020 May; 157(2):357-366. PubMed ID: 32156473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles.
    Griewank KG; Wiesner T; Murali R; Pischler C; Müller H; Koelsche C; Möller I; Franklin C; Cosgarea I; Sucker A; Schadendorf D; Schaller J; Horn S; Brenn T; Mentzel T
    Mod Pathol; 2018 Mar; 31(3):418-428. PubMed ID: 29099504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.
    Møller MB; Ino Y; Gerdes AM; Skjødt K; Louis DN; Pedersen NT
    Leukemia; 1999 Mar; 13(3):453-9. PubMed ID: 10086736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
    Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.